CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that data from the ongoing phase 1 study of tazemetostat (EPZ-6438) will be presented during the American Society of Hematology Meeting being held December 5 – 8 in Orlando, Florida. Tazemetostat is a first-in-class EZH2 inhibitor that is currently being studied in relapsed or refractory B-cell Non-Hodgkin Lymphoma (NHL) and solid tumors.
Help employers find you! Check out all the jobs and post your resume.
